Decision making and dementia: from mechanisms to clinical trials
Lead Research Organisation:
University of Cambridge
Department Name: UNLISTED
Abstract
For people with dementia and related conditions, the changes in memory and behaviour not only affect quality of life but also survival. We study the causes and potential treatments of the changes in behaviour and thinking that affect people with dementia. Rather than look only at the root cause of disease (which is often not known), we look at what is happening in the human brain to change behaviour. In practical terms this could be a better basis for treatment than trying to reverse the effects of faulty genes or unknown environmental triggers. We work with people with different conditions, including Alzheimer’s disease and frontotemporal lobar degeneration, and those with the risk of dementia because of faulty genes of ageing. Part 1 of the research aims to understand and restore behaviour, including the actions one takes and the decisions that lie behind those actions. Apathy and impulsivity are of particular interest. These two problems paradoxically often come together. They point to a worse prognosis. And they have possible treatments to hand. We use computational models of the brain to study how decisions are made in the brain, about what to do and what not to do. We link these models to actual brain function (physiology) and brain chemistry (pharmacology). With these methods, we explain why people differ in their symptoms and response to treatment. We call this precision medicine: precision not in terms of gene or molecules of the brain, but precision of the chemical, physiological and cognitive processes underlying dementia. Part 2 looks at brain function more closely. We use very big sets of data from collaborations (eg. MRC Dementias Platform UK and BIOFIND consortium), and specialist studies at the CBU (eg. Cambridge Centre for Ageing and Neuroscience and scans from people with Alzheimer’s disease, frontotemporal dementia, Progressive Supranuclear Palsy). We use these data to understand how and when dementia begins, and combine different types of brain scanning to explain the biological causes of dementia in people. This leads naturally to ways to target treatments at those most likely to respond.
Technical Summary
The program aims to improve cognition, survival and quality of life of those affected by neurodegenerative disease. It focuses on neurocognitive systems which are proximate to the clinical phenotypes caused by Alzheimer’s disease and frontotemporal lobar degeneration, in the context of normal ageing.
Part 1 seeks to understand and restore behaviours, that are common to many dementias and movement disorders. The term behaviour encompasses the actions one takes and the decisions or goals that lie behind those actions. Apathy and impulsivity are of particular interest, because of their paradoxical positive correlation in disease, their prognostic significance, and their readiness for symptomatic trials. In this program, we formalise behaviour as decisions to act vs to not act (including inhibition) in two complementary types of model: first, the accumulation-to-threshold of the neural basis of evidence; and second, the dynamics of hierarchical networks implementing inferences and predictions of the causes of sensory inputs. The context in which decisions are made is critical, and the program therefore distinguishes transient sensory evidence from enduring contextual beliefs and their predictions. By linking these models to physiological and pharmacological systems, we move towards precision medicine: precision not in terms of gene or molecular aetiology but precision of the chemical, physiological and cognitive processes underlying dementia phenotypes.
Part 2 develops the concept of cognitive physiology further, in terms of generative models of brain function. We draw on large scale data from collaborations (eg. MRC Dementias Platform UK synaptic health theme, Deep and Frequent Phenotyping study, BIOFIND consortium), and CBU based programs (eg. Cambridge Centre for Ageing and Neuroscience and clinical series of Alzheimer’s disease, frontotemporal dementia, Progressive Supranuclear Palsy). The framework of dynamic causal modelling is used to integrate modalities (magnetoencephalography, 7T-MR spectroscopy, PET markers of pathology) to explain phenotypic heterogeneity, identify common mechanisms, and predict treatment response.
Part 1 seeks to understand and restore behaviours, that are common to many dementias and movement disorders. The term behaviour encompasses the actions one takes and the decisions or goals that lie behind those actions. Apathy and impulsivity are of particular interest, because of their paradoxical positive correlation in disease, their prognostic significance, and their readiness for symptomatic trials. In this program, we formalise behaviour as decisions to act vs to not act (including inhibition) in two complementary types of model: first, the accumulation-to-threshold of the neural basis of evidence; and second, the dynamics of hierarchical networks implementing inferences and predictions of the causes of sensory inputs. The context in which decisions are made is critical, and the program therefore distinguishes transient sensory evidence from enduring contextual beliefs and their predictions. By linking these models to physiological and pharmacological systems, we move towards precision medicine: precision not in terms of gene or molecular aetiology but precision of the chemical, physiological and cognitive processes underlying dementia phenotypes.
Part 2 develops the concept of cognitive physiology further, in terms of generative models of brain function. We draw on large scale data from collaborations (eg. MRC Dementias Platform UK synaptic health theme, Deep and Frequent Phenotyping study, BIOFIND consortium), and CBU based programs (eg. Cambridge Centre for Ageing and Neuroscience and clinical series of Alzheimer’s disease, frontotemporal dementia, Progressive Supranuclear Palsy). The framework of dynamic causal modelling is used to integrate modalities (magnetoencephalography, 7T-MR spectroscopy, PET markers of pathology) to explain phenotypic heterogeneity, identify common mechanisms, and predict treatment response.
Organisations
- University of Cambridge (Lead Research Organisation)
- MRC Dementias Platform UK (Collaboration)
- AC Immune (Collaboration)
- University of California, San Francisco (Collaboration)
- OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- AstraZeneca (Collaboration)
- Cardiff University (Collaboration)
- University of Southern California (Collaboration)
- University of Hong Kong (Collaboration)
- Ludwig Maximilian University of Munich (LMU Munich) (Collaboration)
- Utrecht University (Collaboration)
- Life Molecular Imaging (Collaboration)
- University College London (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- University of Gothenburg (Collaboration)
- UK Dementia Research Institute (Collaboration)
- Alzheimer's Research UK (Collaboration)
- National Institute for Health Research (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- Johnson & Johnson (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
Publications
Davenport F
(2023)
Neurodegenerative disease of the brain: a survey of interdisciplinary approaches.
in Journal of the Royal Society, Interface
Ge YJ
(2023)
Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood.
in Biological psychiatry
Holland N
(2023)
Longitudinal Synaptic Loss in Primary Tauopathies: An In Vivo [11 C]UCB-J Positron Emission Tomography Study.
in Movement disorders : official journal of the Movement Disorder Society
King DLO
(2023)
Distinct components of cardiovascular health are linked with age-related differences in cognitive abilities.
in Scientific reports
Related Projects
| Project Reference | Relationship | Related To | Start | End | Award Value |
|---|---|---|---|---|---|
| MC_UU_00030/1 | 01/04/2022 | 31/03/2027 | £2,366,000 | ||
| MC_UU_00030/2 | Transfer | MC_UU_00030/1 | 01/04/2022 | 31/03/2027 | £2,141,000 |
| MC_UU_00030/3 | Transfer | MC_UU_00030/2 | 01/04/2022 | 31/03/2027 | £1,964,000 |
| MC_UU_00030/4 | Transfer | MC_UU_00030/3 | 01/04/2022 | 31/03/2027 | £2,535,000 |
| MC_UU_00030/5 | Transfer | MC_UU_00030/4 | 01/04/2022 | 31/03/2027 | £2,771,000 |
| MC_UU_00030/6 | Transfer | MC_UU_00030/5 | 01/04/2022 | 31/03/2027 | £2,242,000 |
| MC_UU_00030/7 | Transfer | MC_UU_00030/6 | 01/04/2022 | 31/03/2027 | £1,219,000 |
| MC_UU_00030/8 | Transfer | MC_UU_00030/7 | 01/04/2022 | 31/03/2027 | £2,464,000 |
| MC_UU_00030/9 | Transfer | MC_UU_00030/8 | 01/04/2022 | 31/03/2027 | £2,753,000 |
| MC_UU_00030/10 | Transfer | MC_UU_00030/9 | 01/04/2022 | 31/03/2027 | £1,898,000 |
| MC_UU_00030/11 | Transfer | MC_UU_00030/10 | 01/04/2022 | 31/03/2027 | £2,148,000 |
| MC_UU_00030/12 | Transfer | MC_UU_00030/11 | 15/10/2021 | 31/03/2027 | £1,375,000 |
| MC_UU_00030/13 | Transfer | MC_UU_00030/12 | 01/11/2021 | 31/03/2027 | £1,261,000 |
| MC_UU_00030/14 | Transfer | MC_UU_00030/13 | 01/04/2022 | 31/03/2027 | £1,238,000 |
| MC_UU_00030/15 | Transfer | MC_UU_00030/14 | 01/04/2022 | 31/03/2027 | £2,102,000 |
| Description | OLS-DIG Dementia scoping |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | Decision taken to establish the Neurodegeneration initiative within the Dame Barbara Wilson Dementia Mission |
| Description | Sceintific Advisory Board Meber for AI-MIND |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| URL | https://www.ai-mind.eu/partners/ |
| Description | 11.7 UHUF national imaging facility |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | A new UKRI infrastructure award, led by Nottingham University, to establish a new 11.7 T MRI centre. Our role included the case for dementia and Parkinson's disease applications of the new technology; |
| Collaborator Contribution | A multicentre UK consortium, led by Nottingham, for technical, physics, manufacturing and medical impact of the world-leading facility |
| Impact | Award made. Planning ongoing to realise the physical infrastructure. |
| Start Year | 2021 |
| Description | Collaboration Tsvetanov KA & Virginia Newcombe "Understanding the pathogenesis of traumatic vascular injury" |
| Organisation | University of Cambridge |
| Department | Department of Clinical Neurosciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | PI: Virginia Newcombe Title: "Understanding the pathogenesis of traumatic vascular injury" Start date: 01/11/2022 Funding body: Brain Research UK Amount: £292,065 |
| Collaborator Contribution | Collaboration with Prof. Newcombe who received funiding from Brain Research UK. |
| Impact | Funding recieved. |
| Start Year | 2022 |
| Description | Collaboration with Dr Ece Kocagoncu for NTAD (Dr A Jafarian) |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration on data analysis of test-retest data from NTAD. |
| Collaborator Contribution | Availability of NTAD data. |
| Impact | Title: Test-reTest reliability of dynamic casual modelling of resting states MEG data of Alzheimer patients. |
| Start Year | 2022 |
| Description | Collaboration with Dr Nicholas Ashton at the University of Gothenburg |
| Organisation | University of Gothenburg |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | "Synaptic fluid markers in dementia", sharing expertise in field. |
| Collaborator Contribution | "Synaptic fluid markers in dementia", sharing expertise in field. |
| Impact | Advancing biomarker discovery projects. |
| Start Year | 2022 |
| Description | Collaboration with Dr. Gil Rabinovici at the Memory and Aging Center, Department of Neurology, University California San Francisco |
| Organisation | University of California, San Francisco |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration on project "Tau-PET and domain-specific cognitive decline in Alzheimer's disease", cross fertilization of research expertise. |
| Collaborator Contribution | Hosted Post-Doc Dr M. malpetti for 4 month fellowship at UCSF. |
| Impact | Reasearch paper: Malpetti M, La Joie R, Rabinovici GD. Tau beats amyloid in predicting brain atrophy in Alzheimer's disease: implications for prognosis and clinical trials. 2022, Journal of Nuclear Medicine - doi: 10.2967/jnumed.121.263694 |
| Start Year | 2022 |
| Description | Collaboration with Life Molecular Imaging & ACI Immune on FTD |
| Organisation | Life Molecular Imaging |
| Country | Germany |
| Sector | Private |
| PI Contribution | Expertise in PET Imaging of neurodegenerative disease. |
| Collaborator Contribution | PET imaging of genetic FTD - 200,000 cases |
| Impact | In progress |
| Start Year | 2022 |
| Description | Collaboration with Ludwig Maximillian University |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Department | University Clinic of Munich |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | Overlap with group research interests and activiity. Collaboration focuses on ageing and dementia. |
| Collaborator Contribution | Academic expertise. |
| Impact | In progress. |
| Start Year | 2022 |
| Description | ENIGMA MEG working group |
| Organisation | University of Southern California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Supply of a dementia and healthy participants dataset. |
| Collaborator Contribution | TBC |
| Impact | A new collaboration in development, initiated late 2020 and the first meeting took place in January 2021. |
| Start Year | 2021 |
| Description | HKU AI partnership |
| Organisation | University of Hong Kong |
| Country | Hong Kong |
| Sector | Academic/University |
| PI Contribution | A new Cambridge UK to HKU partnership for to develop Artificial Intelligence for Social Good, in biomedicine |
| Collaborator Contribution | Establishing the partnership, developing research strategy, and funding applications, from private and statutory bodies |
| Impact | Pending |
| Start Year | 2022 |
| Description | Hosted Visiting Researcher (University of Cambridge)- Ivana Kancheva |
| Organisation | Utrecht University |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Tsvetanov KA took a lead in the training and supervision of this student. |
| Collaborator Contribution | Ivana Kancheva from Utrecht University hosted at the University of Cambiridge for 10 months in 2022 |
| Impact | Student training and ongoing analytical collaboration. |
| Start Year | 2022 |
| Description | MINDMAPS AD UK |
| Organisation | MRC Dementias Platform UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are collaborating with Imperial on the Mindmaps project, to combine their UCBJ PET data with our MEG data. The aim is to test the link between synaptic density changes and resting state connectivity in Alzheimer's disease. |
| Collaborator Contribution | Dr Eugenii Rabiner of Invicro, leads MIND MAPS - a collaboration between Invicro, the world's leading neuroscience translational imaging centre, six industry partners (AbbVie, Biogen, Celgene, Hamamatsu Photonics, Pfizer and Takeda) and UK's leading academic centres (King's College, Imperial College, University College, Cambridge, Newcastle). Each partner has contributed their particular expert knowledge. Invicro provided the overall scientific design and cutting edge imaging methodologies, the academic partners contribute disease specific knowledge and expertise in patient selection and care. Industry partners provide the knowledge of promising treatment targets and treatments. The collaboration combines these ingredients to ensure that the techniques being developed and tested by the team are truly fit for purpose to support future disease modifying clinical trials. It demonstrates a collaborative way of working that signposts the future of dementia research. |
| Impact | TBC |
| Start Year | 2017 |
| Description | NIHR BRC |
| Organisation | National Institute for Health Research |
| Department | NIHR Cambridge Biomedical Research Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Biomarker development, including cognitive and imaging based deep phenotyping; |
| Collaborator Contribution | Cellular, physiological, radio-chemistry, genetic and pharmaceutical innovations within a pipeline for novel drug discovery; |
| Impact | Adams, N. E., Hughes, L. E., Phillips, H. N., Shaw, A. D., Murley, A. G., Nesbit, D., Cope, T. E., Bevan-Jones, W. R., Passamonti, L., Rowe, J. B. (2020). GABA-ergic dynamics in human frontotemporal networks confirmed by pharmaco magnetoencephalography, Journal of Neuroscience, https://doi.org/10.1523/JNEUROSCI.1689-19.2019. Lewis-Smith, D. J., Wolpe, N., Ghosh, B. C. P., Rowe, J. B. (2020). Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia, Journal of Neurology, https://doi.org/10.1007/s00415-019-09672-8. Jabbari, E., Chelban, V., Holland, N., Jones, P. S., Lamb, R., Rawlinson, C., Guo, T., Costantini, A. A., Tan, M. M. X., Heslegrave, A. J., Roncaroli, F., Klein, j. C., Ansorge, O., Allinson, K. S. J., Jaunmuktane, Z., Holton, J. L., Revesz, T., Warner, T. T., Lees, A. J., Zetterberg, H., Russell, L. L., Bocchetta, M., Rohrer, J. D., Williams, N. M., Grosset, D. G., Burn, D. J., Pavese, N., Gerhard, A., Kobylecki, C., Leigh, P. G., Church, A., Hu, M. T. M., Woodside, J., Houlden, H., Rowe, J. B., Morris, H. R. (2020). Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome, JAMA Neurology, doi:10.1001/jamaneurol.2019.4347. van der Ende, E. L,, Meeter, L. H., Poos, J. M., Panman, J. L., Jiskoot, L. C., Dopper, E. G. P., Papma, J. M., de Jong, F. J., Verberk, I., Teunissen, C. E., Rizopoulos, D., Heller, C., Convery, R. S., Moore, K. M., Bocchetta, M., Neason, M., Cash, D. M., Borroni, B., Galimberti, D., Sanchez-Valle, R., Laforce, Jr R., Moreno, F., Synofzik, M., Graff, C., Masellis, M., Tartaglia, M. C., Rowe, J. B., Vandenberghe, R., Finger, E., Tagliavini, F., de Mendonça, A., Santana, I., Butler, C., Ducharme, S., Gerhard, A., Danek, A., Levin, J., Otto, M., Frisoni, G. B., Cappa, S., Pijnenburg, Y. A. L., on behalf of the GENetic Frontotemporal Dementia Initiative (GENFI), Rohrer, J. D., van Swieten, J. C. (2019). Longitudinal serum neurofilament light chain in genetic frontotemporal dementia: a multicentre cohort study. Lancet Neurology, 18: 1103-1111, https://doi.org/10.1016/S1474-4422(19)30354-0. Shafto, M. A., Henson, R. N., Matthews, F. E., Taylor, J. R., Emery, T., Erzinclioglu, S., Hanley, C., Rowe, J. B., Cusack, R., Calder, A. J., Marslen-Wilson, W. D., Duncan, J., Dalgleish, T., Brayne, C., Cam-CAN, Tyler, L. K. (2019). Cognitive Diversity in a Healthy Aging Cohort: Cross-Domain Cognition in the Cam-CAN Project, Journal of Aging and Health, doi: 10.1177/0898264319878095 [ahead of print], PMID: 31592706 Lansdall, C. J., Coyle-Gilchrist, I. T. S., Vázquez Rodríguez, P., Wilcox, A., Wehmann, E., Robbins, T. W., Rowe, J. B. (2019). Prognostic importance of apathy in syndromes associated with Frontotemporal lobar Degeneration, Neurology, 92(14):e1547-e1557. doi: 10.1212/WNL.0000000000007249, PMID: 30842292, PMC: 6448451. Borchert, B. J., Rittman, T., Rae, C. L., Passamonti, L., Jones, P. S., Vatansever, D., Vazquez-Rodriguez, P., Ye, Z., Nombela, C., Hughes, L. E., Robbins, T. W., Rowe, J. B. (2019). Atomoxetine and citalopram alter brain network organization in Parkinson's disease, Brain Communications, 1:1 fcz013, https://doi.org/10.1093/braincomms/fcz013. PMID: [pending], PMC: [pending]. Nicastro, N., Surendranathan, A., Mak, E., Rowe, J. B.*, O'Brien, J. T.* (2019). 11C-PK11195 PET imaging and white matter changes in Parkinson's disease dementia, Annals of Clinical and Translational Neurology, doi: 10.1002/acn3.50877, PMID: 31507085, PMC: [pending]. Low, A., Mak, E., Malpetti, M., Chouliaras, L., Nicastro, N., Su, L., Holland, N., Rittman, T., Vázquez Rodríguez, P., Passamonti, L., Bevan-Jones, W. R., Jones, P. S., Rowe, J. B.*, O'Brien, J. T.* (2019). Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid-positive mild cognitive impairment is associated with key clinical features, Alzheimer's & Dementia: Diagnosis, Assessment, & Disease Monitoring, 11: 690-699, DOI: https://doi.org/10.1016/j.dadm.2019.08.001, PMID: 31667328, PMC: 6811895. Tavares, T. P., Mitchell, D. G. V., Coleman, K., Shoesmith, C., Bartha, R., Cash, D. M., Moore, K. M., van Swieten, J. C., Borroni, B., Galimberti, D., Tartaglia, M. C., Rowe, J. B., Graff, C., Tagliavini, F., Frisoni, G., Cappa, S., Laforce, R. Jr, de Mendonça, A., Sorbi, S., Wallstrom, G., Masellis, M., Rohrer, J. D., Finger, E. C., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Ventricular volume expansion in presymptomatic genetic frontotemporal dementia, Neurology, doi: 10.1212/WNL.0000000000008386, PMID: 31578297, PMC: [pending]. Passamonti, L., Tsvetanov, K. A., Jones, P. S., Bevan-Jones, W. R., Arnold, R., Borchert, R. J., Mak, E., Su, L., O'Brien, J. T.*, Rowe, J. B.* (2019). Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on cognitive performance, Journal of Neuroscience, doi: 10.1523/JNEUROSCI.2574-18.2019. PMID: 31320450, PMC: 6733539. Jabbari, E., Woodside, J., Guo, T., Magdalinou, N. K., Chelban, V., Athauda, D., Lees, A. J., Foltynie, T., Houlden, H., Church, A., Hu, M. T., Rowe, J. B., Zetterberg, H., Morris, H. R. (2019). Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes, Journal of Neurology, Neurosurgery and Psychiatry, 90(7):768-773. doi: 10.1136/jnnp-2018-320151. PMID: 30867224, PMC: 6585258. Hughes, L. E., Henson, R. N., Pereda, E., Bruña, R., López-Sanz, D., Quinn, A. J., Woolrich, M. W., Nobre, A. C., Rowe, J. B., Maestú, F., BioFIND Working Group (2019). Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography, Alzheimers & Dementia (Amsterdam, Netherlands), 11:450-462. doi: 10.1016/j.dadm.2019.04.009. PMID: 31431918, PMC: 6579903. Shaw, A. D., Hughes, L. E., Moran, R., Coyle-Gilchrist, I., Rittman, T., Rowe, J. B. (2019). In Vivo Assay of Cortical Microcircuitry in Frontotemporal Dementia: A Platform for Experimental Medicine Studies. Cerebral Cortex. 2019. doi: 10.1093/cercor/bhz024. PMID: 31216360. van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M.C., Piccini, P., Pineda-Pardo, J. Á., Rektorová, I., Rodríguez-Oroz, M., Rominger, A., Seppi, K., Stoessl, A. J., Tessitore, A., Thobois, S., Kaasinen, V., Wenning, G., Siebner, H. R., Strafella, A. P., Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers & Dementia (Amsterdam, Netherlands). 11:301-309. doi: 10.1016/j.dadm.2019.01.011. PMID: 30984816, PMC: 6446052. Rittman, T., Borchert, R., Jones, P. S., van Swieten, J., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M. C., Graff, C., Tagliavini, F., Frisoni, G. B., Laforce, R. Jr, Finger, E., Mendonça, A., Sorbi, S., Rohrer, J. D., Rowe, J. B., GENetic Frontotemporal Dementia Initiative (GENFI) (2019). Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia, Neurobioly of Aging, 77:169-177. doi: 10.1016/j.neurobiolaging.2018.12.009, PMID: 30831384; PMC: 6491498. Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. I., O'Brien, J. T., Rowe, J. B. (2019). In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Annals of Clinical Translational Neurology, 6(2):373-378. doi: 10.1002/acn3.683. PMID: 30847369; PMC: 6389753. |
| Start Year | 2017 |
| Description | NTAD Collaboration with UCL-UK DRI Plasma Tau Analysis |
| Organisation | UK Dementia Research Institute |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | NTAD study provides blood samples obtained from participants with Alzheimer's disease. |
| Collaborator Contribution | Collaboration with Dr Henrik Zetterberg & Dr Amanda Heslegrave, UK DRI Fluid Biomarker Laboratory at UCL, for plasma tau analysis obtained from NTAD participants. |
| Impact | TBC |
| Start Year | 2020 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Alzheimer's Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | AstraZeneca |
| Department | Astra Zeneca |
| Country | United States |
| Sector | Private |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Johnson & Johnson |
| Department | Janssen Pharmaceuticals |
| Country | United States |
| Sector | Private |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | NTAD new therapeutics in Alzheimer's disease |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | DPUK EM theme |
| Collaborator Contribution | New biomarker platform for dementia - Cambridge, Oxford, Janssen, JnJ, Lilly, AZ, ARUK and DPUK - |
| Impact | Annual workshop |
| Start Year | 2017 |
| Description | PREVENT 7T |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Application of 7T technology to understand the effects of inherited risk of dementia |
| Collaborator Contribution | Coordination of national PREVENT study of people at risk of dementia |
| Impact | Pending |
| Start Year | 2019 |
| Description | SENDeR & TENDeR UCL/Oxford collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | All research activities take place in Cambridge as the Primary Research Site. |
| Collaborator Contribution | UCL and Oxford site have been added as Patient Identification Sites. |
| Impact | TBC |
| Start Year | 2020 |
| Description | SENDeR & TENDeR UCL/Oxford collaboration |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | All research activities take place in Cambridge as the Primary Research Site. |
| Collaborator Contribution | UCL and Oxford site have been added as Patient Identification Sites. |
| Impact | TBC |
| Start Year | 2020 |
| Description | Study Agreement with AC Immune on FTD Project |
| Organisation | AC Immune |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | PI and Post0Doctoral Researcher will actively run the "Evaluation of PI-2620 PET in Familial Frontotemporal Dementia" study. |
| Collaborator Contribution | EUR 161000 in funding |
| Impact | Outcomes pending |
| Start Year | 2022 |
| Description | Supervisor with Caius Higher Aspiration Scheme - Rebecca Williams (Rowe Group) |
| Organisation | University of Cambridge |
| Department | Gonville and Caius College |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Supervisor to 6 students (Year 12) |
| Collaborator Contribution | Aspiration Scheme |
| Impact | Student development. |
| Start Year | 2022 |
| Description | UK7T Network |
| Organisation | Cardiff University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | UK7T Network |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The UK7T network promotes the acceleration of ultrahigh field MRI for biomedical research, including harmonisation, standardisation, sharing and joint research programs across the seven UK7T networks and liaison with the European EUFIND consortium for 7T MRI. |
| Collaborator Contribution | Data sharing, sequence sharing, training opportunities, QC and translational pilot studies |
| Impact | Multi-disciplinary - neuroscience, physics, chemistry, data sciences, medicine, Prior to DPUK collaboration there was a MRC Partnership award. |
| Start Year | 2021 |
| Description | All About Brians - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Virtual contribution at Storyhouse Theatre Chester, UK. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Big Biology Day - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Live at Hills Road Sixth Form, collaboration with ARUK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Brain Models & Pipecleaner Neurons (Rebecca Williams - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Collaboration with CHaOS - live at school in St. Neots, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | CHaOS Summer Roadshow (Rebecca Williams - Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Live at Poacher Scout's Jamboree (over 6000 in attendance) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Coping with Exam Stress - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | In collaboration with Study Together |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dementia Chatathon - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Collaboration with Dementia Researcher, watched via Youtube, Twiter & Twitch |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dementia Researcher Podcasts and Fundraising events - Dr M Malpetti |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | https://www.dementiaresearcher.nihr.ac.uk/tag/dr-maura-malpetti/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.dementiaresearcher.nihr.ac.uk/tag/dr-maura-malpetti/ |
| Description | Dr M Malpetti Invited career panel speaker at the Biomarker UCL course for PhD students |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Invited career panel speaker at the Biomarker UCL course for PhD students (London, 18/05/2022) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Dr Maura Malpetti (Rowe Group): Oral Presentation at DPUK Translation 2023 Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation on "Post mortem validation of in vivo PET imaging: test case of inflammation in progressive supranuclear palsy" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.dementiasplatform.uk/research-hub/translation-2023/early-career-researchers-workshop-and... |
| Description | Effective Note Taking Strategies: Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Collaboration with Study Together |
| Year(s) Of Engagement Activity | 2022 |
| Description | Filmed Charity Broadcast for PSP Association |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | PSPA broadcast. |
| Year(s) Of Engagement Activity | 2022 |
| Description | How to Tackle an Academic Paper - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | How to Tackle an Academic Paper |
| Year(s) Of Engagement Activity | 2022 |
| Description | How to tackle Academic Teading and Writing - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Summer CAMP collaboration. |
| Year(s) Of Engagement Activity | 2022 |
| Description | In Conversation at Christmas - Broadcast on Dementia |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | In conversation at Christmas is a stimulating discussion, covering some of the progress made in research in 2022, and looking ahead to 2023. Hear from our Chief Scientific Officer, Prof James Rowe and Head of Research, Dr Rosa Sancho and ambassador for Alzheimer's Research UK, Scott Mitchell. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=Vwp8QNIJSZ4 |
| Description | Lecture to MPhil Students in Basic and Translational Neuroscience - Dr M Malpetti |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Lecture on the MPhil in Basic and Translational Neuroscience, University of Cambridge (Cambridge, 24/10/2022): "Dementia and neurodegenerative diseases: what have we learned from brain imaging?" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Let's Talk Science - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Skyped in to Birmingham, USA |
| Year(s) Of Engagement Activity | 2022 |
| Description | Let's Talk Science! Skype a Scientist, Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Schools |
| Results and Impact | Engagement via Skype a Scientist to Missouri, USA. |
| Year(s) Of Engagement Activity | 2022 |
| Description | News coverage of finding that 7T MRI predicts new drug response in Parkinsons disease |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Report on finding that ultra-powerful brain scanners could offer hope for the treatment of previously-untreatable symptoms in Parkinson's disease, a new study suggests. See links below: https://www.independent.co.uk/news/health/patients-cognition-university-of-cambridge-b2080470.html https://www.upi.com/Health_News/2022/05/16/7T-MRI-Parkinsons-study/9901652724269/ https://www.thetimes.co.uk/article/advanced-7t-mri-scanner-could-benefit-parkinsons-patients-fcqqp2797 https://healthcare-in-europe.com/en/news/7t-brain-scanners-parkinson-s-disease.html https://www.cambridgeindependent.co.uk/news/high-powered-mri-scanners-could-identify-parkinson-s-patient-9254685/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.itv.com/news/anglia/2022-05-17/new-scanners-offer-hope-for-treating-parkinsons-disease |
| Description | Oral Presentation - Dr K Stockton "Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia. GENFI winter meeting International meeting of research study |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation @ ADPD Barcelona 20222- Dr M Malpetti |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "In vivo PET imaging of inflammation as a prognostic tool in frontotemporal dementia" - ADPD conference (Barcelona, 03/2022) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation Dr D Street at Midlands Neurological Society Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation Non-motor markers predict survival in PSP |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral Presentation: Caius Higher Aspiration Scheme - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Caius Higher Aspiration Scheme |
| Year(s) Of Engagement Activity | 2023 |
| Description | Oral Presentation: Translational neuropsychiatry @ BIOMAG 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Talk title "Translational neuropsychiatry" |
| Year(s) Of Engagement Activity | 2022 |
| Description | PSPA Research Day - Oral Presentation Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | "Pick's disease and Progressive supranuclear palsy Prevalence and Incidence study (PiPPIN)" 3/2/23 PSPA Research Day Research day for patients and carers, organised by the PSP association |
| Year(s) Of Engagement Activity | 2022 |
| Description | Pint of Science: Atoms to Galaxies |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Events held live in Cambridge UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster Presentation Association of British Neurologists - Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation titled: Pick's disease and Progressive supranuclear palsy Prevalence and Incidence study (PiPPIN) |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster Presentation International Society for FTD - Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | "Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia". France |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster Presentation: Clinical Neurosciences Day, Cambridge University - Dr K Stockton |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster on "Metabolomic effects of sporadic, genetic and pre-symptomatic frontotemporal dementia". With poster blitz presentation. In person, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Sutton Trust MEG Talks - Rebecca Williams (Rowe Group) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Event held at the MRC Cognition Brain Unit |
| Year(s) Of Engagement Activity | 2022 |